Product Description
EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an investigational eFlow nebulizer (PARI Pharma GmbH).Ê (Sourced from: http://test.pharmabiz.com/news/elevation-pharma-presents-positive-golden-1-study-results-evaluating-ep-101-in-copd-patients-at-ers-congress-70972)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elevation
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GOLDEN-2 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2013-04-01 |
|
2011-001810-32 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2011-12-19 |
|
GOLDEN-1 Study | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2011-12-01 |
|
2010-018987-17 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-11-23 |